This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aoki, Y. Articles by Takahashi, T. Search for Related Content PubMed PubMed Citation Articles by Aoki, Y. Articles by Takahashi, T.

Use of Adoptive Transfer of Tumor-infiltrating Lymphocytes Alone or in Combination with Cisplatin-containing Chemotherapy in Patients with Epithelial Ovarian Cancer¹

Department of Obstetrics and Gynecology, Niigata University School of Medicine, 1, Asahimachi-dori, Niigata 951 [Y. A., K. T., S. K., K. T.]; Department of Obstetrics and Gynecology, Sanjo General Hospital 5, Ijima, Sanjo, Niigata 955 [M. T.]; Department of Obstetrics and Gynecology, Niigata City Hospital, Shichikuyama, Niigata 951 [A. T.]; and Department of Obstetrics and Gynecology, Niigata Cancer Center 2, Kawagishichou, Niigata 951 [T. T.], Japan

Lymphocytes isolated from fresh human epithelial ovarian tumors can be expanded in the presence of recombinant interleukin-2, and some CD8 antigen-positive lymphocytes can lyse autologous fresh tumor cells. We treated 7 patients with advanced or recurrent epithelial ovarian cancers, using the adoptive transfer of these tumor-infiltrating lymphocytes (TILs) following a single i.v. injection of cyclophosphamide. One case of disappearance (complete response) and 4 cases of >50% decrease of tumor (partial response) were reported (14.3 and 57.1%, respectively). Regression of tumors in the ovary, liver, lung, and lymph node, both primaries and metastases, lasted for 3–5 months. Furthermore, 10 patients were treated alternately with a cisplatin-containing chemotherapeutic regimen and the adoptive transfer of TILs. Seven cases of complete regression and 2 cases of partial regression of cancer were reported. Four of the 7 patients with a complete response have had no recurrence for >15 months of follow-up. It appears that this experimental technique of adoptive transfer of TILs achieves high response rates even without recombinant interleukin-2 administration and that the prospect of combined therapy using TILs and cisplatin offers hope for increasing the cure rate and long-term survival.

¹ This work was supported in part by a Grant-in-Aid from the Ministry of Health and Welfare for the Comprehensive 10-Year Strategy for Cancer Control.

² To whom requests for reprints should be addressed.

Received 1/11/90. Accepted 1/17/91.

This article has been cited by other articles:

				A. Kawamura Jr, T. Sekine, M. Sekiguchi, S. Yanoma, A. Kaneko, T. Haneda, Y. Moriya, K.-i. Hayasaka, and T. Kakizoe Six-year Disease-free Survival of a Patient with Metastatic Eyelid Squamous Cell Carcinoma and Colon Adenocarcinoma after Repeated Postoperative Adoptive Immunotherapy Jpn. J. Clin. Oncol., June 1, 2000; 30(6): 267 - 271. [Abstract] [Full Text] [PDF]